10-K/A: Spyre Therapeutics Files Amended 10-K to Include Hyperlinks to Exhibits
Annual Report Amendment
Spyre Therapeutics has filed an amendment to its annual report on Form 10-K to include hyperlinks to exhibits that were previously incorporated by reference.
Summary
- Spyre Therapeutics filed an amendment to its annual report on Form 10-K, specifically to add hyperlinks to exhibits that were previously incorporated by reference in the original filing.
- This amendment does not update or modify any other disclosures or reflect any events occurring after the original filing on February 29, 2024.
- The company's principal executive and financial officers have provided certifications as required by the Securities Exchange Act of 1934.
- The amendment includes a list of exhibits with hyperlinks, covering various agreements, plans, and other relevant documents.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing to correct a technical issue, indicating a neutral to slightly positive sentiment due to the company's adherence to compliance.
Positives
- The company is fulfilling its regulatory requirements by filing the amendment.
- The inclusion of hyperlinks makes the exhibits more accessible for review.
Management Comments
- Cameron Turtle, Chief Executive Officer, certified that the report does not contain any untrue statements or omissions of material facts.
- Scott Burrows, Chief Financial Officer, certified that the report does not contain any untrue statements or omissions of material facts.
Industry Context
This filing is a standard regulatory requirement for publicly traded companies and does not indicate any specific industry trends or competitive actions.
Comparison to Industry Standards
- The filing of a 10-K/A amendment to correct a technical issue such as missing hyperlinks is a common occurrence in SEC filings.
- Many companies file amendments to their annual reports for various reasons, including correcting errors or adding missing information.
Stakeholder Impact
- The amendment ensures that stakeholders have access to all relevant documents through the provided hyperlinks.
- This action demonstrates the company's commitment to transparency and regulatory compliance.
Key Dates
| Date | Description |
|---|---|
| June 30, 2023 | The last business day of the Registrant's second fiscal quarter, used to calculate the market value of non-affiliate common equity. |
| December 31, 2023 | End of the fiscal year for which the original 10-K was filed. |
| February 21, 2024 | Date of the latest practicable date for the number of outstanding shares of common stock. |
| February 29, 2024 | Date of the original 10-K filing. |
| March 1, 2024 | Date of the amended 10-K/A filing and certifications by the CEO and CFO. |
Keywords
10-K, Amendment, Hyperlinks, Exhibits, SEC Filing, Financial Reporting, Spyre Therapeutics, Regulatory Compliance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.